Baar, 18 March 2025 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide-based active pharmaceutical ingredients, published today the invitation to the fourth annual General Meeting, ...

ALBANY, N.Y., March 17, 2025 (GLOBE NEWSWIRE) -- Curia Global, Inc. (Curia), a leading contract research, development and manufacturing organization, today announced expansion plans to its Glasgow, UK ...

more than doubling current GMP batch size. Already known for its antibody drug conjugates (ADCs), lipid nanoparticles (LNPs), lyophilization development, complex formulation and development ...

Surf Bio, a biopharmaceutical company transforming the delivery of antibodies and biologics, announced today the appointment of Doug Hecker as Head of Technical Operations. With over 30 years of ...

Curia Global, Inc. (Curia), a leading contract research, development and manufacturing organization, today announced expansion plans to its Glasgow, UK ...

On the one hand, they can leverage our development teams, cutting-edge technologies, and world-class facilities in a traditional CDMO partnership – with both our GLP-1 and biologics services in high ...

The company said that, based on a pharmacokinetic study, it has plumped for a once-daily, modified-release formulation of GLP-1 agonist danuglipron that will start dose optimisation studies later ...

Novo Nordisk has filed another Citizen's Petition with the FDA seeking to block compounding pharmacies in the US from making versions of one of its GLP-1 agonist drugs. The latest attempt focuses ...

Guidance, tips and best practices for benefits managers to reduce their benefit spend while producing competitive benefit packages for employees. With health care representing the biggest ...